Características Clínicas da Alopecia Frontal Fibrosante no Brasil: Série de 59 Pacientes by Barreto Rocha, Vanessa et al.
315
Artigo Original
5HYLVWD63'9)URQWDOÀEURVLQJDORSHFLDLQ%UD]LO9DQHVVD%5RFKD/HWLFLD$&RQWLQ3ULVFLOD.DNL]DNL&DUOD-0DFKDGR0iULR&3LUHV
Cidia Vasconcellos.
Características Clínicas da Alopecia Frontal Fibrosante 
no Brasil: Série de 59 Pacientes       
Vanessa Barreto Rocha1, Leticia Arsie Contin2, Priscila Kakizaki1, Carla Jorge Machado1, Mário Cézar Pires1, Cidia Vasconcellos3
1IAMSPE, Hospital do Servidor Público Estadual de São Paulo, São Paulo, Brasil 
2Hospital do Servidor Público Municipal, Departamento de Dermatologia, São Paulo, Brasil 
3UFMG, Departamento of de Medicina Preventiva e Social, Faculdade de Medicina, Belo Horizonte - MG - Brazil
RESUMO – ,QWURGXomR A alopecia frontal fibrosante (AFF) foi inicialmente descrita em 1994 na Austrália, Europa e América do 
Norte, e este é o maior estudo sobre as características da AFF na América Latina. 0pWRGRV Através de questionários e revisão 
dos processos clínicos, descrevemos as características de 59 pacientes com AFF, quanto à forma clínica, características indivi-
duais e uso de produtos cosméticos. 5HVXOWDGRV A idade média dos pacientes foi de 58,4 anos (35-84 anos). A duração da 
doença variou de seis meses a 20 anos (mediana 5 anos). A maioria das mulheres encontrava-se na menopausa e (83,1%) e era 
não fumadora (83,1%). Cinco por cento tinham pelo menos uma doença autoimune associada, principalmente hipotireoidis-
mo (13,6%). Seis pacientes (15%) apresentavam líquen plano pigmentoso e dez pápulas faciais (25%). Alopecia dos supracílios 
ocorreu em 50 (84,7%) e no corpo em 47 (79,7%). Pápulas faciais foram mais prevalentes em mulheres na pré-menopausa. 
&RQFOXVmR Estudar a epidemiologia da AFF pode ajudar a entender a fisiopatologia dessa doença epidémica e este artigo traz 
algumas semelhanças e diferenças com estudos publicados anteriormente sobre a AFF, como maior frequência em mulheres na 
pós-menopausa, associação com hipotireoidismo e irritação facial com o uso de produtos cosméticos.
PALAVRAS-CHAVE – Alopecia/epidemiologia; Brasil; Líquen Plano. 
Clinical Characteristics of Frontal Fibrosing Alopecia 
in Brazil: A Series of 59 Patients    
ABSTRACT – ,QWURGXFWLRQ Clinical characteristics of frontal fibrosing alopecia (FFA) have been studied since its description in 
1994 in Europe, North America and Australia, and the present study is the largest on FFA features in Latin America. 0HWKRGV 
This study, through questionnaire and medical records, describes characteristics of a Brazilian population of 59 patients with FFA, 
concerning clinical forms, individual features and use of cosmetic products. 5HVXOWV Mean patients’ age was 58.4 years (range 
35-84y). Duration of disease varied from six months to 20y (median 5y). Most women were postmenopausal (83.1%) and non-
-smokers (83.1%). Five percent had at least one associated autoimmune disease, most commonly hypothyroidism (13.6%). Six of 
40 patients (15%) had lichen planus pigmentosus and ten had facial papules (25%). Eyebrow alopecia occurred in 50 (84.7%), 
and body hair loss in 47 (79.7%). Facial papules were more prevalent in premenopausal women. &RQFOXVLRQ Studying FFA epide-
miology may help understanding the pathophysiology of this epidemic disease and this study highlights similarities and differences 
to previously published studies in FFA, such as greater frequency in postmenopausal women, association with hypothyroidism and 
facial irritation with cosmetic products.  
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INTRODUCTION
Frontal fibrosing alopecia (FFA) is a chronic cicatricial 
lymphocytic alopecia that turned epidemic in recent years.1 It 
affects mainly postmenopausal women, usually starting at the 
eyebrows or fronto-temporal area of hair implantation.2,3 The 
optimal treatment has not been established yet.3 Clinical and 
clinicopathologic studies of FFA have been done in Europe, 
North America and Australia,3-5 and the present study is the 
largest on FFA characteristics in Latin America.
The etiopathogenesis of FFA is still unknown. It is assumed 
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that hormonal, genetic and environmental factors are invol-
ved.6-9 As most patients with FFA are postmenopausal women, 
in addition to reports of disease improvement with the use of 
5-alpha-reductase inhibitors, the hormonal issue was one of 
the first to be raised.3 
Familial cases of FFA indicated a possible genetic basis for 
the disease and have been described since 2008.10 The gene-
tics of FFA have recently been described. In locus 6p21.1 there 
would be an indication that the association is determined by 
HLA B*07:02, which would confer a fivefold increase in the 
risk of FFA.11
Environmental factors are supposed to be involved in the 
pathogenesis of FFA, mainly because it is a recently described 
disease (1994), and it develops in older ages. In 2016, two 
studies suggested the association of FFA and the use of suns-
creens and facial creams.12,13
METHODS
All patients with clinical and histological diagnosis of FFA 
(n=80) observed between 2014 to 2017 (new cases and follow-
-up) from Dermatology department of Hospital do Servidor 
Municipal de São Paulo, in Brazil, were invited to respond to 48 
questions regarding aspects of the disease and usual habits, 
especially exposure to personal products (Supplement 1). Fifty-
-nine accepted to collaborate. The questionnaire was adminis-
tered by a trained dermatologist. The protocol was approved 
by the Ethics Committee (CAAE nº 62445116.8.0000.5442). 
The clinical patterns (based upon hair line recession)14-16 
(Fig. 1) were defined through patients’ photos by a single ob-
server. Clinical data as the presence of lichen planus pigmen-
tosus (Fig. 2), facial papules (Fig. 3), eyebrow and body hair 
loss, and data on treatment durations, disease stability were 
defined through the clinical review of charts. No laboratory or 
histopathological exams were performed for the study.
Categorical data were expressed as percentage, and 
numerical data on average +- SD or median with interval 
between quartiles when appropriate. For numerical data com-
parison were made through unpaired t-test (normal data) or 
through Mann-Whitney test (non-normal data). For categorical 
data, Chi-square test (n>5) or Fisher's exact test (n<5) were 
used. The level of significance was considered as p<0.05.
Figure 1  
A B C
A B
Figura 2
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Age                 years                   Gender: Woman               Men                              Phototype
Profession:                                                                          Are you currently working on this?  Yes               No
AFF Running Time:
Health problems:
Medicinal products in use orally or topically, including vitamins and dietary supplements:
Menopausal?   Yes               No                    HRT?   Yes               No
Oral contraceptive?   Yes               No           What?                                                     How long?
Smoker?   Yes               No                    ex-smoker how many years ago?
Ethylist?   Yes               No                    ex-alcoholist how many years ago?
Increased sweating on the face or scalp?                        (specify where and how long)
Proven allergy to any medication?   Yes               No                    What?
Proven allergy to any cosmetic product?   Yes               No                    What?
Have you ever undergone chemical peels on your face?   Yes               No                    How long ago?
Have you had laser treatments on your face?   Yes               No                    What? 
How long ago?                                      How many times?
Does your skin become red easily?   Yes               No                    When?
Do you often use your products at work or leisure, such as chalk, modeling clay, clay, rubbers, 
ceramics or the like?   Yes               No                    Name which:
Are you in current treatments for this disease?   Yes               No                    How long ago?
Have you had previous treatments for this disease?   Yes               No                    
What and for how long?
Is it itchy at the hair loss site?   Yes               No                    Burning?   Yes               No                    
Pain?   Yes               No                    Loss of body hair?   Yes               No                    Where?
Loss of eyebrows?   Yes               No                    Other skin, mouth or vagina / penis lesions?   Yes               No                    
Where?
Product Name Current Usage? Use at the time of diagnosis?
Facial moisturizers   Sunscreens   Shampoos
Conditioners    Hair care products: dyes, straighteners, gels, combing creams
Others to remember: 
Epidemiological evaluation of patients treated at the HSPM Trichology 
Outpatient Clinic from 2014 to 2017
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RESULTS
All 59 patients were female, the mean age was 58.4 years 
(range 35-84y), of whom 31 were Caucasians (52.5%), most 
of Fitzpatrick's phototype III (45%) and 28 afro-descendants 
(47.5%). Duration of illness (from onset of patient's percep-
tion of the disease until the time of the questionnaire) varied 
from six months to 20 years, with a median of five years. The 
mean age at onset of the disease was 52 years and the time 
to diagnosis was on average six years. Most women were 
postmenopausal (n= 49; 83.1%), 14 (28.6%) of whom under 
hormonal replacement therapy, and 49 were non-smokers 
(83.1%). Five percent had an associated autoimmune disea-
se, most commonly hypothyroidism (13.6%) (Table 1).
As for aesthetic procedures on the face, 11 had already 
made chemical peels and nine, laser treatments. Thirty-two 
reported regular use of sunscreen at the time of diagnosis 
(54.2%) and 33 used facial moisturizers (55.9%). Twenty pa-
tients reported intolerance or facial irritation while using cos-
metics (33.9%), nine with sunscreens, 13 with moisturizers/
anti-aging creams, 8 with foundation and 2 with perfumes.
Thirty-four patients reported facial erythema (57.6%), 19 
with sun exposure (32.2%). Twelve patients (20.3%) reported 
allergies to drugs, mainly to antibiotics; the leading one was 
penicillin.
Twenty-one (35.6%) had already straightened their hair, 
44 had dyed their hair (74.6%) and 16 (27.1%) had already 
undergone both procedures.
Clinical pattern could be defined in 40 patients by pho-
tos, according to Moreno-Arrones et al,14,16 Contin et al16 and 
Rossi et al15 (Table 2). The most frequently found clinical pat-
tern was diffuse or type 2 (n=19; 47.5%), followed by linear 
or type 1 (n=9, 22.5%). The patches pattern affected four 
(10.0%) of the patients, the pseudofringe two (5.0%) and the 
pattern similar to androgenetic alopecia affected three (7.5%) 
patients. 
Regarding the characteristics of the disease, six of 40 
patients (15%) had lichen planus pigmentosus, and ten had 
papules on the face (25%). No patient presented lesions of 
lichen planus in other regions.
Concerning disease symptoms, six (10%) patients presen-
ted pain and/or burning, and 31 (51.5%) reported pruritus. 
Eyebrow alopecia occurred in 50 (84.7%), and body hair loss 
in 47 (79.7%), mainly in the upper limbs.
Respecting treatment, 16 (27.1%) patients are not curren-
tly being treated, and the most commonly used medications 
were doxycycline, hydroxychloroquine and finasteride, in va-
rious combinations, with topical drugs as well. Single drug 
treatment did not occur. 
Response to treatment could be assessed in 41 patients 
through medical records and photos, with stabilization of the 
clinical picture in 11 patients (26.8%).
DISCUSSION
In search for its etiopathogenesis, the number of publi-
shed articles on FFA has grown, and environmental factors 
have been suggested.5,12,13
This study, through questionnaire and medical records, 
describes the characteristics of a Brazilian population of 59 
patients with FFA, concerning clinical forms, individual cha-
racteristics and use of cosmetic products. 
When comparing present data with the literature, we ob-
served a balanced division between Caucasians and Afro-
-descendants (p>0.05), which should reflect the great 
miscegenation of our population, as it can be seen in another 
Brazilian study.17
Our data reflects a slightly earlier age of onset of FFA 
(52y) compared to the literature.4,18 As in previous studies, 
most patients are postmenopausal, but unlike these, the pre-
valence of women under hormone replacement therapy is 
lower (28.6%) compared some reports.19
Eyebrow alopecia was very frequent in our series, as well 
as hair loss in the limbs and genital region. Facial papules 
were more prevalent in premenopausal women, but with no 
difference in relation to ethnicity, differently from Mervis et 
al.20 The predominant clinical pattern was diffuse FFA (II) si-
milarly to Moreno-Arrones et al.14 
The use of moisturizers and anti-aging creams was less 
frequent than in Moreno-Arrones study,5 but the use of suns-
creens was larger.
As for comorbidities, hypothyroidism was common among 
patients with FFA, with a lower prevalence than in other stu-
dies,4,19 but similar to Brazilian studies.17,21 In the authors ex-
perience, patients who were treated for FFA with doxycycline, 
hydroxychloroquine or finasteride had a slightly better control 
of the symptoms and clinical signs, such as positive pull test 
and pruritus, but progression seems to have its natural way 
and is limited to the natural history of the disease, which is 
still unknown.7 Loss of body hair did not seem to be reversed 
Figura 3
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Table 1 - &OLQLFDOSURÀOHRI%UD]LOLDQ))$SDWLHQWVFRPSDUHGWROLWHUDWXUH
Study This study JDD review4 Vaño-Galvan3 Chile18 Mayo Clinic 6HFFKLQ%UD]LO17 .XVDQR%UD]LO21
Number of patients 59 932 289 27 148 16 38
Sex 59 F 96.9% F 289 F 26 F/1 M 148 F 16 F 38 F
Age
mean 58.4 y
(35-84)
---
60 y (32-91)#
p=0.433
---
mean 62 y #
p=0.233
61 y #
p=0.239
Age at onset 52.02 y 55.6 y --- 57.5 y --- --- 44 y / 59 y**
FFA duration median 5 y 3.7 y --- --- --- --- ---
Age at diagnosis --- 60.6 y --- --- 62.1 y --- ---
Race
white 30 
(50.8%)
black 29 (49.2%)
white 86%
p<0.001
black 12%
p<0.001
--- ---
white 89.2
p<0.001
black 5.4%
p<0.001
black 56.3%
p=0.648
Post-menopausal 49 (83.1%)
84.14%  
p=0.832
--- ---
87.2%
p=0.442
15 (93.8%)
p=0.283
---
Pre-menopausal 10 (16.9%)
15.6%
p=0.790
--- --- --- ---
HRT 14/49 (28.6%) ---
19%
p=0.123
---
63.3%
p<0.001
---
16 (42.1%)
p=0.188
Comorbidities
Hypothyroidism 8 (13.6%)
1.4% 
p=0.004
20.8 
p=0.204
---
44.6% 
p<0.001
3 (18.8%) 
p=0.603
11 (28.9%) 
p=0.064
SAH 20 (33.9%)
5.9 % 
p<0.001
--- ---
37.2% 
p=0.656
8 (50%) 
p=0.238
18 (47,4%) 
p=0.093
DM 12 (20.3%) ---
0.3% 
p<0.001
3.4% 
p<0.001
2 (12.3%)
p=0.475
2 (5.3%) 
p=0.039
Dyslipidemia 7 (11.9%)
10.2% 
p=0.677
--- ---
45.3% 
p<0.001
14 (36.8%) 
p=0.004
Autoimmune 
diseases 
3 (5%) 
SLE 1, PM-1 
Hepatitis 1
3.1% 
p=0.422
---
41 (27.7%)***
SLE 5(3.4%)  
p=0.598
14 @
SLE 4 (25%)
p<0.001
&
SLE 1(2.6%)
p=0.753
Osteoporosis 4 (6.8%)
4% 
p=0.297
--- ---
15.5% 
p<0.093
---
1 (2.63%) 
p=0.367
Clinical symptoms and signs
Pruritus 31(51.5%)
66.7%
p=0.042
10(62.5%)
p=0.478
Pain 6 (10.2%)
27.7%
p=0.007
4 (25.0%)
p=0.122
Facial erythema 22(37.3%)
Alopecia 
   Eyebrows 50(84.7%)
70.4%
p=0.036
60.1%
p=0.004
14 (87.5%)
p=0.782
34 (89.5%)
p=0.505
   Axillae 15(25.4%)
15.2%
p= 0.093
15.5%
p=0.963
6 (37.5%)
21 (55%)
p=0.003
   Genital 11(18.6%)
11.7%
p=0.203
7.4%
p=0.036
   Limbs 41(69.5%)
7.4%
p<0.001
9.5%
p<0.001
5 (31.25%)
p=0.005
   Eyelashes 1 (1.7%)
1.4%
p=0.820
Lichen planus 
pigmentosus
5 (8.5%)
18.2%
p=0.143
5(31.6%) a
p=0.018
1 (2.6%) b
p=0.244
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Table 1 - &OLQLFDOSURÀOHRI%UD]LOLDQ))$SDWLHQWVFRPSDUHGWROLWHUDWXUH&RQW
Study This study JDD review4 Vaño-Galvan3 Chile18 Mayo Clinic 6HFFKLQ%UD]LO17 .XVDQR%UD]LO21
Number of patients    27 148 16 38
Environemental factors
&RVPHWLFXVH&XUUHQW
Moisturizers
17 (28.8%)
Past – 7
---
89.6
p<0.001
--- --- --- ---
Sunscreens 
46 (77.9%)
Past – 30
---
48.1
p<0.001
--- --- ---
23 (60.5%)
p=0.064
Antiaging/ 
antiwrinkle
25 (42.4%)
Past – 22
---
78.5
p<0.001
--- --- --- ---
Hair dyes
38 (64.4%)
Past – 32
--- --- --- --- ---
33 (86.4%)
p=0.05
Hair straightener
12 (20.3%)
Past – 13
--- --- --- --- --- ---
Cosmetic “allergy” 20 (33.4%) --- --- --- --- --- ---
Smoking 10 (16.9%) --- --- --- --- --- ---
Medications (n=130)
Chloroquine 13 (22%)
7 (5.4%)
p<0.001
---
26%
p=0.684
---
7 (43.8%)
p= 0.082
27 (71.1%)
p<0.001
Minoxidil 18 (30.5%) --- ---
55.6%
p=0.026
---
14 (87.5%)
p< 0.001
---
Isotretinoin 1 (1.7%) --- ---
0  
p=0.496
--- --- ---
Topical steroids 8 (13.6%)
33 (25,4%)
p<0.001
---
100%
p<0.001
---
10 (62.5%)
p< 0.001
---
Intralesional 
steroid 
1 (1.7%)
21 (16.2%)
p=0.004
---
0
p=0.496
--- --- ---
Doxycycline 21 (35.6%) --- --- --- ---
5 (31.8%)
p=0.746
---
Finasteride  
Dutasteride
17 (28.8%)
20 (15.4%)
p=0.032
---
29.6%
p=0.940
---
10 (62.5%)
p=0.13
17 (44.8%)
p=0.110
Tacrolimus 8 (13.6%) --- --- --- ---
11 (68.8%)
p< 0.001
---
Methotrexate 1 (1.7%) --- --- --- --- --- ---
Clinical Stability 28/39 (71.8%) --- --- ---
40/95 (42.1%)
p=0.002
---
20 (52.6%)
p= 0.083
Note: # standard deviation estimated by amplitude / 4 
* “Allergy” to cosmetics was documented with the patient's report of some reaction to the use of cosmetic products. It does not mean true allergy. Patch 
test was not performed. ##- no current smokers
** Age of onset in pre- and postmenopausal patients
*** Sjögren syndrome 6 (4.1%), scleroderma 2 (1.4%), psoriasis 11 (7.4%), IBD 8 (5.4%), celiac disease 3 (2%), rheumatoid arthritis 2 (1.4%)
@ 5DLE, vitiligo 3 (18.8%), psoriasis 1 (6.3%), Hashimoto’s thyroiditis 2 (12.3%)
& vitiligo 2 (5.3%), psoriasis 1 (2.6%)
a- 1 case of oral lichen planus (6.3%); b- 1 case of nail lichen planus (2.6%)
'/(GLVFRLGOXSXVHU\WKHPDWRVXV'0GLDEHWHVPHOOLWXV+57KRUPRQHUHSODFHPHQWWKHUDS\,%'LQÁDPPDWRU\ERZHOGLVHDVH/33LJOLFKHQSODQXV
pigmentosus); s. (syndrome); SAH (systemic arterial hypertension); SLE (systemic lupus erythematosus); PM (polymyositis)
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or affected by treatment. Some patterns seem to have a better 
prognosis than others, like the patchy, masculine and pseu-
do-fringe types. Others, like FFA type two and patients with 
other autoimmune diseases, such as lupus erythematosus, 
polymyositis and autoimmune hepatitis, seem to have a more 
aggressive behaviour. 
We used hydroxychloroquine and 5-alpha-reductase inhi-
bitors similarly to Chileans18 and Secchin in Brazil,17 but the 
former less frequently and the latter more frequently than re-
ported in Valesky et al,4 and Kusano in Brazil.21 In our series, 
the use of topical corticosteroids and intralesional infiltration 
of corticosteroids was lower as compared with most other stu-
dies.4 This may reflect the current fear of atrophy with injecta-
ble corticosteroids in Brazil.
Comparing FFA treatments with the literature is still a di-
fficult task. Each research centre uses a stability parameter 
(photos, LPPAI, ruler measurement etc.) and single treatments 
are not attempted. Indeed there are multiple treatment proto-
cols, which makes comparisons fragile.
Possible limitations of this study are recall bias, the retros-
pective nature of the study and lack of generalization.
FFA presents certain peculiarities in each of the popula-
tion groups studied. Particular features in this group are a 
greater frequency in post-menopausal women, association 
with hypothyroidism and facial irritation with cosmetic pro-
ducts usually used. Studying epidemiology of FFA may help 
understanding the pathophysiology of this epidemic disease 
and the present study shows similarities and differences from 
previously published studies.
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Table 2 - &OLQLFDOSDWWHUQVRIWKH))$%UD]LOLDQSDWLHQWVSDWLHQWVHYDOXDWHGRXWRIFRPSDUHGWROLWHUDWXUH
Clinical pattern Our study 40 patients
Moreno-Arrones
242 patients
Statistical difference
Only eyebrow alopecia 1 (2.5%) -
Patches 4 (10.0 %) -
Linear (type 1) 9 (22.5 %) 118 (48.8 %) p=0.002
Difuse (type 2) 19 (47.5 %) 109 (45.0 %) p=0.769
Pseudofringe (type 3) 2 (5.0 %) 15 (6.2%) p=0.768
AGA like 3 (7.5 %) -
1RGHÀQHGSDWWHUQ 2 (5 %) -
Table 3 - Presence of facial papules in our study (40 patients evaluated) compared to literature. 
Mervis20 Our study p
With papules 24 (26%) 10/40 (25%) 0.760
Premenopausal with papules 12/30 (40%) 4/7 (57.1%) 0.410
Postmenopausal with papules 11/57 (19%) 6/33 (18.2%) 0.938
Total 87 40
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